• Mon news: Novartis in $745M radiopharma pact. Novo launches Wegovy in China. COVID-era telehealth prescribing extended. Hims & Hers GLP-1 tracker. Promising Gilead liver disease trial. See more on our front page

Roger Perlmutter Town Hall

Quote
Anonymous said:
In his E-mail today, Rupert is heading Discovery and Rich Tillya still heading the Preclinical. All the franchises are gone. I was disappointed he didn't make more leadership changes, since we're not going to be able to get rid of the abusive low morale creating middle managers if he still has the same leadership on top. I was impressed with his talks though, and hope he has some real way of restoring dignity to the bench scientists as he talked about (before they all leave).
Click to expand...

what about Boston? Is the Montreal guy still in charge there?
 




























Onc pretty much dead. Steve has been let go couple month ago, Gary G … gone, Leigh gone … more info next week ….. Guess research is now run by the two with funny british accents, and yes they are tall, very important
 




Research Leadership Team (RLT) GO TEAM......LOL

Rupert Vessey will lead Discovery and Early Development, including biology research necessary to identify targets, medicinal chemistry for the elaboration of therapeutics with ideal pharmaceutical properties, and early clinical development activities designed to characterize the behavior of these compounds in human subjects,

Rich Tillyer will have responsibility for Preclinical Development, including process chemistry. As previously announced, Rich has also assumed a corporate responsibility as part of the team, led by Willie Deese, that is developing an improved operating model for Merck & Co,

Linda Schaffer will lead our Project Management group, and will have responsibility for all of our performance metrics. Project teams that previously reported through Linda’s group will now move to their respective development areas, as appropriate. Linda will also serve as the project lead for the team led by Willie Deese, on which Rich Tillyer also serves,

Barry Gertz will head the Clinical Development organization, including clinical operations, the clinical therapeutic areas, and the Japan development organization,

Dennis Erb will be responsible for our Regulatory Affairs and Safety organization, which will be expanded to include our emerging market activities,

Rich Murray will lead research in Biologics and Vaccines, including process development activities necessary to provide materials for clinical trials and the transfer of commercially viable manufacturing processes to MMD,

I am elevating the Licensing organization to report directly to me. I intend to reconfigure this group to adopt a more operational focus. An external search for a new head of licensing is underway and will be the subject of a future announcement. Roger Pomerantz will continue to lead this function during this interim period.
 




































Finally, the Montreal Mafia is broken. The capos are gone and the remaining foot soldiers are running scared. With new therapeutic area leadership, this is Boston's last chance to deliver. At least science has a real chance to breathe now. Before, the emphasis was always on milestones (get there whatever the cost) and flashy PowerPoint presentations ('hide the negative results!'). Roger will sniff out the remaining rats and BS artists in no time. The few true scientists left in Boston are really looking forward to the next few months. Let's hope this is not a false dawn.
 




Anonymous said:
Finally, the Montreal Mafia is broken. The capos are gone and the remaining foot soldiers are running scared. With new therapeutic area leadership, this is Boston's last chance to deliver. At least science has a real chance to breathe now. Before, the emphasis was always on milestones (get there whatever the cost) and flashy PowerPoint presentations ('hide the negative results!'). Roger will sniff out the remaining rats and BS artists in no time. The few true scientists left in Boston are really looking forward to the next few months. Let's hope this is not a false dawn.
Click to expand...

Haha, remember them talking about leadership on every occasion? It is science, stupid!
 








Top Bottom
Back
Quote